tiprankstipranks
Resmed (MX:RMD)
:RMD
Mexico Market
RMD
Resmed
RESEARCH TOOLSreports

Resmed (RMD) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

RMD Analyst Ratings

Moderate Buy
13Ratings
Moderate Buy
4 Buy
9 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Resmed
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RMD Stock 12 Month Forecast

Average Price Target

$4,208.96
▲(24.71% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Resmed in the last 3 months. The average price target is $4,208.96 with a high forecast of $5,594.99 and a low forecast of $3,846.56. The average price target represents a 24.71% change from the last price of $3,375.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3418":"$3,418","5595":"$5,595","3962.25":"$3,962.3","4506.5":"$4,506.5","5050.75":"$5,050.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5594.9924832,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.59K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4208.960254407272,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.21K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3846.5573322,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.85K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3418,3962.25,4506.5,5050.75,5595],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3419,3586.384037169231,3753.7680743384617,3921.152111507692,4088.536148676923,4255.920185846154,4423.304223015384,4590.6882601846155,4758.072297353846,4925.456334523076,5092.840371692308,5260.224408861538,5427.608446030768,{"y":5594.9924832,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3419,3479.766173415944,3540.532346831888,3601.298520247832,3662.064693663776,3722.83086707972,3783.5970404956643,3844.363213911608,3905.129387327552,3965.8955607434964,4026.66173415944,4087.4279075753843,4148.1940809913285,{"y":4208.960254407272,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3419,3451.8890255538463,3484.778051107692,3517.6670766615384,3550.5561022153847,3583.4451277692306,3616.334153323077,3649.223178876923,3682.1122044307695,3715.0012299846153,3747.8902555384616,3780.7792810923074,3813.6683066461537,{"y":3846.5573322,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4694.075,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5146.241,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5322.579,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5081.411,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4417.066,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4427.975,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4435.327,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4435.327,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4445.611,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4018.8,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 104,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3705.772,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 114,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3716.1,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 93,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3419,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$5,595Average Price Target$4,209Lowest Price Target$3,847
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on MX:RMD
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
07/20/26
We are publishing our thoughts on ResMed’s late-June field safety corrective action (FSCA) on Astral ventilators and updating our model for the moving pieces of the MatrixCare divestiture and Noctrix acquisition— the latter of which results in lowered fiscal 2027 EPS. after exchanging emails with the company and assessing prior Astral field actions, we are not as concerned as others on the Street since it is a small part of the business and ResMed is taking a controlled approach to replacing vents in the field. That said, we acknowledge that it is another negative headline to create concerns over a stock with already negative sentiment and can cause stock volatility. Noctrix, we estimated our fiscal 2027 EPS needed be reduced by about $0.33, or 3%.
RBC Capital Analyst forecast on MX:RMD
Craig Wong-Pan
RBC Capital
RBC Capital
$4,825.68→$4,091.34
Hold
21.22%
Upside
Downgraded
07/16/26
ResMed downgraded to Sector Perform from Outperform at RBC CapitalResMed downgraded to Sector Perform from Outperform at RBC Capital
Mizuho Securities Analyst forecast on MX:RMD
Anthony Petrone
Mizuho Securities
Mizuho Securities
$4,108.82→$3,846.56
Buy
13.97%
Upside
Reiterated
07/15/26
ResMed price target lowered to $220 from $235 at MizuhoResMed price target lowered to $220 from $235 at Mizuho
Morgan Stanley Analyst forecast on MX:RMD
David Bailey
Morgan Stanley
Morgan Stanley
$4,021.4
Hold
19.15%
Upside
Reiterated
07/13/26
Resmed Maintained at Hold as Astral Ventilator Safety Notice Clouds Outlook; $230 Price Target Unchanged
Jefferies Analyst forecast on MX:RMD
Matthew Taylor
Jefferies
Jefferies
$3,933.98
Hold
16.56%
Upside
Reiterated
07/10/26
Jefferies Issues a Hold Rating on Resmed (RMD)
Citi Analyst forecast on MX:RMD
Laura Sutcliffe
Citi
Citi
$4,720.77→$4,108.82
Hold
21.74%
Upside
Downgraded
07/10/26
Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD) and Eli Lilly & Co (NYSE: LLY)
Needham Analyst forecast on MX:RMD
Michael Matson
Needham
Needham
―
Hold
―
Reiterated
07/08/26
Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD) and Prime Medicine, Inc. (NASDAQ: PRME)
Stifel Nicolaus Analyst forecast on MX:RMD
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
$4,108.82
Hold
21.74%
Upside
Reiterated
07/08/26
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), Meiragtx Holdings (NASDAQ: MGTX) and Resmed (NYSE: RMD)
Bank of America Securities Analyst forecast on MX:RMD
Lyanne Harrison
Bank of America Securities
Bank of America Securities
$5,594.99
Buy
65.78%
Upside
Reiterated
07/08/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Tvardi Therapeutics (NASDAQ: TVRD), Resmed (NYSE: RMD) and Zimmer Biomet Holdings (NYSE: ZBH)
Wells Fargo Analyst forecast on MX:RMD
Nathan Treybeck
Wells Fargo
Wells Fargo
$3,968.95→$3,933.98
Hold
16.56%
Upside
Assigned
07/08/26
Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD), Abbott Laboratories (NYSE: ABT) and Vera Therapeutics (NASDAQ: VERA)
KeyBanc Analyst forecast on MX:RMD
Brett Fishbin
KeyBanc
KeyBanc
$5,070.46→$4,650.84
Buy
37.80%
Upside
Assigned
06/22/26
KeyBanc Sticks to Their Buy Rating for Resmed (RMD)
Piper Sandler Analyst forecast on MX:RMD
Adam Maeder
Piper Sandler
Piper Sandler
$4,073.85
Hold
20.71%
Upside
Reiterated
05/06/26
Piper Sandler Remains a Hold on Resmed (RMD)
Robert W. Baird Analyst forecast on MX:RMD
David Rescott
Robert W. Baird
Robert W. Baird
$4,441.03→$3,933.98
Hold
16.56%
Upside
Reiterated
05/01/26
ResMed price target lowered to $225 from $254 at BairdResMed price target lowered to $225 from $254 at Baird
J.P. Morgan Analyst forecast on MX:RMD
Chris Cooper
J.P. Morgan
J.P. Morgan
―
Buy
―
Initiated
04/15/26
J.P. Morgan Keeps Their Buy Rating on Resmed (RMD)
Evercore ISI Analyst forecast on MX:RMD
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
$5,245.31→$4,458.51
Buy
32.10%
Upside
Reiterated
04/13/26
ResMed price target lowered to $255 from $300 at Evercore ISIResMed price target lowered to $255 from $300 at Evercore ISI
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
William Blair Analyst forecast on MX:RMD
Brandon Vazquez
William Blair
William Blair
―
Buy
―
Reiterated
07/20/26
We are publishing our thoughts on ResMed’s late-June field safety corrective action (FSCA) on Astral ventilators and updating our model for the moving pieces of the MatrixCare divestiture and Noctrix acquisition— the latter of which results in lowered fiscal 2027 EPS. after exchanging emails with the company and assessing prior Astral field actions, we are not as concerned as others on the Street since it is a small part of the business and ResMed is taking a controlled approach to replacing vents in the field. That said, we acknowledge that it is another negative headline to create concerns over a stock with already negative sentiment and can cause stock volatility. Noctrix, we estimated our fiscal 2027 EPS needed be reduced by about $0.33, or 3%.
RBC Capital Analyst forecast on MX:RMD
Craig Wong-Pan
RBC Capital
RBC Capital
$4,825.68→$4,091.34
Hold
21.22%
Upside
Downgraded
07/16/26
ResMed downgraded to Sector Perform from Outperform at RBC CapitalResMed downgraded to Sector Perform from Outperform at RBC Capital
Mizuho Securities Analyst forecast on MX:RMD
Anthony Petrone
Mizuho Securities
Mizuho Securities
$4,108.82→$3,846.56
Buy
13.97%
Upside
Reiterated
07/15/26
ResMed price target lowered to $220 from $235 at MizuhoResMed price target lowered to $220 from $235 at Mizuho
Morgan Stanley Analyst forecast on MX:RMD
David Bailey
Morgan Stanley
Morgan Stanley
$4,021.4
Hold
19.15%
Upside
Reiterated
07/13/26
Resmed Maintained at Hold as Astral Ventilator Safety Notice Clouds Outlook; $230 Price Target Unchanged
Jefferies Analyst forecast on MX:RMD
Matthew Taylor
Jefferies
Jefferies
$3,933.98
Hold
16.56%
Upside
Reiterated
07/10/26
Jefferies Issues a Hold Rating on Resmed (RMD)
Citi Analyst forecast on MX:RMD
Laura Sutcliffe
Citi
Citi
$4,720.77→$4,108.82
Hold
21.74%
Upside
Downgraded
07/10/26
Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD) and Eli Lilly & Co (NYSE: LLY)
Needham Analyst forecast on MX:RMD
Michael Matson
Needham
Needham
―
Hold
―
Reiterated
07/08/26
Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD) and Prime Medicine, Inc. (NASDAQ: PRME)
Stifel Nicolaus Analyst forecast on MX:RMD
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
$4,108.82
Hold
21.74%
Upside
Reiterated
07/08/26
Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (NASDAQ: CMPS), Meiragtx Holdings (NASDAQ: MGTX) and Resmed (NYSE: RMD)
Bank of America Securities Analyst forecast on MX:RMD
Lyanne Harrison
Bank of America Securities
Bank of America Securities
$5,594.99
Buy
65.78%
Upside
Reiterated
07/08/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Tvardi Therapeutics (NASDAQ: TVRD), Resmed (NYSE: RMD) and Zimmer Biomet Holdings (NYSE: ZBH)
Wells Fargo Analyst forecast on MX:RMD
Nathan Treybeck
Wells Fargo
Wells Fargo
$3,968.95→$3,933.98
Hold
16.56%
Upside
Assigned
07/08/26
Analysts Offer Insights on Healthcare Companies: Resmed (NYSE: RMD), Abbott Laboratories (NYSE: ABT) and Vera Therapeutics (NASDAQ: VERA)
KeyBanc Analyst forecast on MX:RMD
Brett Fishbin
KeyBanc
KeyBanc
$5,070.46→$4,650.84
Buy
37.80%
Upside
Assigned
06/22/26
KeyBanc Sticks to Their Buy Rating for Resmed (RMD)
Piper Sandler Analyst forecast on MX:RMD
Adam Maeder
Piper Sandler
Piper Sandler
$4,073.85
Hold
20.71%
Upside
Reiterated
05/06/26
Piper Sandler Remains a Hold on Resmed (RMD)
Robert W. Baird Analyst forecast on MX:RMD
David Rescott
Robert W. Baird
Robert W. Baird
$4,441.03→$3,933.98
Hold
16.56%
Upside
Reiterated
05/01/26
ResMed price target lowered to $225 from $254 at BairdResMed price target lowered to $225 from $254 at Baird
J.P. Morgan Analyst forecast on MX:RMD
Chris Cooper
J.P. Morgan
J.P. Morgan
―
Buy
―
Initiated
04/15/26
J.P. Morgan Keeps Their Buy Rating on Resmed (RMD)
Evercore ISI Analyst forecast on MX:RMD
Unknown Analyst
Evercore ISI
Not Ranked
Evercore ISI
$5,245.31→$4,458.51
Buy
32.10%
Upside
Reiterated
04/13/26
ResMed price target lowered to $255 from $300 at Evercore ISIResMed price target lowered to $255 from $300 at Evercore ISI
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Resmed

3 Months
Lyanne HarrisonBank of America Securities
Success Rate
15/28 ratings generated profit
54%
Average Return
+3.38%
reiterated a buy rating 20 days ago
Copying Lyanne Harrison's trades and holding each position for 3 Months would result in 53.57% of your transactions generating a profit, with an average return of +3.38% per trade.
1 Year
Lyanne HarrisonBank of America Securities
Success Rate
18/28 ratings generated profit
64%
Average Return
+7.34%
reiterated a buy rating 20 days ago
Copying Lyanne Harrison's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +7.34% per trade.
2 Years
Lyanne HarrisonBank of America Securities
Success Rate
14/28 ratings generated profit
50%
Average Return
+6.48%
reiterated a buy rating 20 days ago
Copying Lyanne Harrison's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +6.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RMD Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
1
2
3
Buy
45
104
113
91
29
Hold
6
1
11
11
19
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
51
105
125
104
51
In the current month, RMD has received 32 Buy Ratings, 19 Hold Ratings, and 0 Sell Ratings. RMD average Analyst price target in the past 3 months is 4,208.96.
Each month's total comprises the sum of three months' worth of ratings.

RMD Financial Forecast

RMD Earnings Forecast

Next quarter’s earnings estimate for RMD is $50.44 with a range of $48.17 to $51.95. The previous quarter’s EPS was $49.86. RMD beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 56.79% of the time in the same period. In the last calendar year RMD has Outperformed its overall industry.
Next quarter’s earnings estimate for RMD is $50.44 with a range of $48.17 to $51.95. The previous quarter’s EPS was $49.86. RMD beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 56.79% of the time in the same period. In the last calendar year RMD has Outperformed its overall industry.

RMD Sales Forecast

Next quarter’s sales forecast for RMD is $25.48B with a range of $25.23B to $26.11B. The previous quarter’s sales results were $24.96B. RMD beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 48.83% of the time in the same period. In the last calendar year RMD has Outperformed its overall industry.
Next quarter’s sales forecast for RMD is $25.48B with a range of $25.23B to $26.11B. The previous quarter’s sales results were $24.96B. RMD beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 48.83% of the time in the same period. In the last calendar year RMD has Outperformed its overall industry.

RMD Stock Forecast FAQ

What is MX:RMD’s average 12-month price target, according to analysts?
Based on analyst ratings, Resmed’s 12-month average price target is 4,208.96.
    What is MX:RMD’s upside potential, based on the analysts’ average price target?
    Resmed has 24.71% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Resmed a Buy, Sell or Hold?
          Resmed has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 9 hold ratings and 0 sell ratings.
            What is Resmed’s share price target?
            The average share price target for Resmed is 4,208.96. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $5,594.99 ,and the lowest forecast is $3,846.56. The average share price target represents 24.71% Increase from the current price of $3,375.
              What do analysts say about Resmed?
              Resmed’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of Resmed?
                To buy shares of MX:RMD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.